Specific compounds found in exhaled breath may help diagnose lung cancer in its early stages, according to a study released Jan. 28 at The Society of Thoracic Surgeons annual meeting.
The discovery was made when Michael Bousamra, MD, and researchers from the University of Louisville examined patients with suspicious lung lesions.
Using a silicone microprocessor and mass spectrometer, the researchers tested exhaled breath for the presence and levels of specific volatile organic compounds in patients with suspected lung cancer that was detected on computed tomography scans. The researchers then matched their findings with pathologic and clinical results.
Although the data are preliminary, we found that patients with an elevation of three or four cancer-specific carbonyl compounds was predictive of lung cancer in 95% of patients with a pulmonary nodule or mass, Bousamra said in a news release. Conversely, the absence of elevated VOC levels was predictive of a benign mass in 80% of patients.
The carbonyl compounds used in the study analysis are a subset of volatile organic compounds called aldehydes and ketones, which are organic compounds with a carbon double-bonded to oxygen. These compounds are at very low concentrations and are produced by the human body.
Instead of sending patients for invasive biopsy procedures when a suspicious lung mass is identified, our study suggests that exhaled breath could identify which patients may be directed for an immediate intraoperative biopsy and resection, Bousamra said.
The researchers found that elevated carbonyl concentrations returned to normal following complete resection in patients with a malignant nodule.
The novelty of this approach includes the simplicity of sample collection and ease for the patient, Bousamra said.
The silicone microprocessor used in the study was developed at the University of Louisville. It was coated with an amino-oxy compound that binds to carbonyl compounds in exhaled breath.